Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis [Peripheral Vascular Disease]
Conclusions—
Adjunctive elamipretide during PTRA was associated with attenuated postprocedural hypoxia, increased RBF, and improved kidney function in this pilot trial. These data support a role for targeted mitochondrial protection to minimize procedure-associated ischemic injury and to improve outcomes of revascularization for human atherosclerotic renal artery stenosis.
Clinical Trial Registration—
URL: https://www.clinicaltrials.gov. Unique identifier: NCT01755858.
Source: Circulation: Cardiovascular Interventions - Category: Cardiology Authors: Saad, A., Herrmann, S. M. S., Eirin, A., Ferguson, C. M., Glockner, J. F., Bjarnason, H., McKusick, M. A., Misra, S., Lerman, L. O., Textor, S. C. Tags: Nephrology and Kidney, Imaging, Atherosclerosis, Peripheral Vascular Disease, Stenosis Source Type: research
More News: Angiography | Angioplasty | Cardiology | Cardiovascular | Clinical Trials | Heart | Mitochondrial Disease | MRI Scan | Perfusion | Peripheral Vascular Disease (PVD) | Study | Urology & Nephrology